Juvederm Volbella with Lido (2x1 ml)

Volbella works by utilizing a smooth HA matrix that binds to water in the dermis without the "puffiness" associated with older-generation fillers. The Vycross cross-linking provides a cohesive gel that moves naturally with facial expressions. Unlike the Restylane range, which often uses NASHA technology for firmer projection, Volbella prioritizes softness and seamless integration into superficial tissues.

Juvederm Volbella is not recommended for women who are currently breastfeeding. While the HA is localized, the lack of clinical trials evaluating the transfer of components like lidocaine into breast milk requires a cautious approach. It is best to wait until the nursing period has concluded.

The formulation contains 15 mg/ml of cross-linked Hyaluronic Acid of non-animal origin, utilizing Vycross Technology, and is supplemented with 0.3% Lidocaine hydrochloride for a comfortable patient experience.

Dosage is individualized based on the depth of the lines being treated or the desired lip hydration level. A single 1 ml syringe is typically sufficient for correcting perioral lines or providing a subtle refresh. Practitioners should assess if 0.5 ml of lip filler is enough for the patient's aesthetic goals before administering the full volume.

Common side effects include minor localized swelling, redness, and potential purple bruising at the injection site. Due to the Vycross technology, inflammatory swelling is usually minimal. To ensure a quick recovery, patients should follow our expert aftercare guide. Any persistent blanching or intense pain must be evaluated immediately for vascular occlusion.

Patients should refrain from consuming alcohol for at least 24 hours before and 48 hours after the procedure. Alcohol is a vasodilator that can increase blood flow to the treatment site, potentially worsening post-filler swelling and increasing the visibility of injection-site bruising.

This treatment is strictly contraindicated during pregnancy. There is no definitive clinical safety data regarding the use of Vycross-based HA injectables during fetal development. We adhere to the highest safety standards and advise postponing all elective fillers until after childbirth.